HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress.

AbstractAIM:
Ezetimibe, an inhibitor of cholesterol intestinal absorption, is a lipid lowering agent. However, anti-atherogenic effects of ezetimibe have not been fully elucidated. Therefore, the objective in this study was to clarify the vascular protective effects of ezetimibe in patients with hypercholesterolemia.
METHODS:
Ezetimibe was administered to 20 patients with hypercholesterolemia (group E), and 20 age- and sex-matched patients with hypercholesterolemia were followed as controls (group C). Difference in metabolic profiles and cardiovascular surrogate markers before ezetimibe treatment and after 12 weeks of ezetimibe treatment were statistically evaluated.
RESULTS:
Ezetimibe treatment significantly reduced serum levels of low-density lipoprotein cholesterol (LDL-C) and malondialdehyde-modified low-density lipoprotein (MDA-LDL). In addition, the values of body mass index, body weight, waist circumference, plasma HbA1c and urinary albumin were significantly decreased in group E compared to those in group C. On the other hand, high-density lipoprotein cholesterol (HDL-C) and adiponectin levels were significantly increased in group E compared to those in group C. The values of brachial-ankle pulse wave velocity (ba-PWV), mean arterial blood pressure (m-ABP), and % of flow-mediated dilation (FMD) were significantly improved in group E. Furthermore, ultrasonic studies demonstrated amelioration of the vascular stiffness of common carotid arteries in group E but not in group C. These vascular protective effects of ezetimibe were statistically correlated with the decreased values of MDA-LDL and MDA-LDL-to-LDL-C ratio but not with those of LDL-C.
CONCLUSION:
Ezetimibe has a lipid lowering-independent vascular protective effect in patients with hypercholesterolemia through decreasing oxidative stress.
AuthorsHirotsugu Kurobe, Ken-ichi Aihara, Mayuko Higashida, Yoichiro Hirata, Masako Nishiya, Yuki Matsuoka, Tamotsu Kanbara, Taisuke Nakayama, Hajime Kinoshita, Mikio Sugano, Eiki Fujimoto, Ayako Kurobe, Noriko Sugasawa, Takashi Kitaichi, Masashi Akaike, Masataka Sata, Toshio Matsumoto, Tetsuya Kitagawa
JournalJournal of atherosclerosis and thrombosis (J Atheroscler Thromb) Vol. 18 Issue 12 Pg. 1080-9 ( 2011) ISSN: 1880-3873 [Electronic] Japan
PMID22027560 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Azetidines
  • Lipids
  • Ezetimibe
Topics
  • Aged
  • Azetidines (pharmacology, therapeutic use)
  • Case-Control Studies
  • Endothelium, Vascular (drug effects, physiopathology)
  • Ezetimibe
  • Humans
  • Hypercholesterolemia (physiopathology)
  • Lipids (blood)
  • Male
  • Middle Aged
  • Oxidative Stress (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: